Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Hematology"
DOI: 10.1007/s12185-020-02825-w
Abstract: Lenalidomide and dexamethasone (Rd) treatment is common for patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem-cell transplantation. Daratumumab plus Rd (D-Rd) is effective and well tolerated for treating relapsed or refractory multiple… read more here.
Keywords: transplant ineligible; newly diagnosed; japanese patients; multiple myeloma ... See more keywords
Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A network meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2021.103504
Abstract: BACKGROUND Despite major therapeutic advances, the rational choice of the most appropriate first-line regimen in newly diagnosed transplant-ineligible multiple myeloma (TIE-MM) is currently undefined. AIM We aimed to identify the most effective first-line treatment for… read more here.
Keywords: transplant ineligible; line; first line; ineligible multiple ... See more keywords
Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features.
Sign Up to like & getrecommendations! Published in 2021 at "Current problems in cancer"
DOI: 10.1016/j.currproblcancer.2021.100788
Abstract: Lenalidomide and low-dose dexamethasone (Rd) are a standard treatment for older adults with multiple myeloma (MM). Lenalidomide monotherapy has rarely been evaluated for newly diagnosed transplant-ineligible MM patients. This multicenter phase II trial evaluated a… read more here.
Keywords: response adapted; ineligible patients; transplant ineligible; newly diagnosed ... See more keywords
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Sign Up to like & getrecommendations! Published in 2022 at "Leukemia"
DOI: 10.1038/s41375-021-01488-8
Abstract: In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) versus lenalidomide/dexamethasone (Rd). We present a subgroup analysis of MAIA by frailty… read more here.
Keywords: transplant ineligible; non frail; frailty; lenalidomide dexamethasone ... See more keywords
Efficacy and toxicity of carfilzomib- or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000030715
Abstract: Background: Multiple myeloma is a clonal disorder of malignant plasma cells that comprises approximately 10% of hematologic malignancies. The aim of this study was to investigate the efficacy and toxicity of carfilzomib- or bortezomib-based regimens… read more here.
Keywords: based regimens; ineligible patients; transplant ineligible; bortezomib based ... See more keywords
Real‐world outcomes with bortezomib‐containing regimens and lenalidomide plus dexamethasone for the treatment of transplant‐ineligible multiple myeloma: a multi‐institutional report from the Canadian Myeloma Research Group database
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Haematology"
DOI: 10.1111/bjh.17350
Abstract: Bortezomib‐containing regimens (BCRs) represented standard, first‐line therapy for transplant‐ineligible multiple myeloma (TIMM) in Canada until the introduction of lenalidomide and low‐dose dexamethasone (Ld). However, little comparative data exist to inform the selection of regimens. We… read more here.
Keywords: transplant ineligible; containing regimens; myeloma; ineligible multiple ... See more keywords
Network meta‐analysis of first‐line treatments in transplant‐ineligible multiple myeloma patients
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Haematology"
DOI: 10.1111/ejh.13407
Abstract: Multiple myeloma (MM) is a complex disease. Lack of direct comparisons among treatments and incorporation of new alternatives make it necessary to perform studies that allow for clinical decision‐making. A network meta‐analysis (NMA) was developed… read more here.
Keywords: multiple myeloma; network meta; transplant ineligible; meta analysis ... See more keywords
Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2017-09-772681
Abstract: Addition of brentuximab vedotin, a CD30-targeted antibody-drug conjugate, and the programmed death 1 (PD-1) inhibitors nivolumab and pembrolizumab to the armamentarium for transplant-ineligible relapsed/refractory classical Hodgkin lymphoma has resulted in improved outcomes, including the potential… read more here.
Keywords: transplant ineligible; relapsed refractory; hodgkin lymphoma; classical hodgkin ... See more keywords
The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Personalized Medicine"
DOI: 10.3390/jpm12020130
Abstract: Background: This study aimed to evaluate the cost-effectiveness of treating transplant-ineligible myeloma patients with either a bortezomib plus thalidomide plus dexamethasone (VTD) or a bortezomib plus melphalan plus prednisolone (VMP) treatment in Taiwan. Methods: Newly… read more here.
Keywords: myeloma patients; cost effectiveness; bortezomib plus; transplant ineligible ... See more keywords
Treatment Considerations for Transplant-Ineligible Multiple Myeloma.
Sign Up to like & getrecommendations! Published in 2021 at "Oncology"
DOI: 10.46883/onc.2021.3504.0170
Abstract: While significant advances have been made in the treatment of multiple myeloma, the management of the transplant-ineligible (TI) patient population remains challenging. The individuals enrolled in clinical trials for newly diagnosed TI patients, or those… read more here.
Keywords: transplant ineligible; considerations transplant; treatment; treatment considerations ... See more keywords